statistiche ricercatore

DE LERMA BARBARO, ANDREA

Distribuzione geografica

Continente	#
NA - Nord America	5.085
EU - Europa	4.777
AS - Asia	1.080
Continente sconosciuto - Info sul continente non disponibili	5
SA - Sud America	5
OC - Oceania	2
Totale	10.954

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	4.979
IT - Italia	2.507
UA - Ucraina	953
TR - Turchia	373
SE - Svezia	366
VN - Vietnam	328
FI - Finlandia	252
DE - Germania	232
CN - Cina	229
IE - Irlanda	204
SG - Singapore	110
CA - Canada	105
GB - Regno Unito	104
FR - Francia	100
IN - India	24
JP - Giappone	12
BE - Belgio	11
RU - Federazione Russa	11
NL - Olanda	9
CZ - Repubblica Ceca	7
CH - Svizzera	6
EU - Europa	5
AT - Austria	4
RS - Serbia	4
BR - Brasile	3
ES - Italia	2
LT - Lituania	2
NZ - Nuova Zelanda	2
AZ - Azerbaigian	1
CO - Colombia	1
DK - Danimarca	1
GL - Groenlandia	1
GR - Grecia	1
PE - Perù	1
PH - Filippine	1
PK - Pakistan	1
PL - Polonia	1
TW - Taiwan	1
Totale	10.954

Salva come PNG Salva come JPEG

Città	#
Milan	1.840
Jacksonville	723
Chandler	529
Fairfield	453
Woodbridge	354
Ashburn	323
Wilmington	257
Princeton	245
Ann Arbor	229
Izmir	229
Nyköping	216
Dublin	204
Dearborn	194
Seattle	189
Houston	167
Dong Ket	155
Boardman	148
Cambridge	134
Rome	125
Como	103
Singapore	100
Toronto	95
Beijing	92
San Mateo	92
New York	58
San Diego	55
Dallas	44
Ogden	38
Chicago	34
Düsseldorf	29
Verona	23
Pune	22
Hefei	20
Los Angeles	19
Helsinki	18
Santa Clara	16
Nanjing	15
London	13
Brussels	11
Guangzhou	11
Kunming	10
Tokyo	10
Norwalk	9
Jinan	8
Munich	8
Redwood City	8
Ponte Lambro	7
Washington	7
Auburn Hills	6
Rozzano	6
Villanova D'asti	6
Falls Church	5
Fuzhou	5
Vanzaghello	5
Zhengzhou	5
Belgrade	4
Casorezzo	4
Changsha	4
Hebei	4
Hounslow	4
Seveso	4
Thamesmead	4
Voghera	4
Xian	4
Amsterdam	3
Chiswick	3
Costa Mesa	3
Edinburgh	3
Frankfurt am Main	3
Huzhou	3
Indiana	3
Nanchang	3
Olomouc	3
Ottawa	3
Phoenix	3
San Francisco	3
Shenyang	3
Varese	3
Wenzhou	3
Wuhan	3
Zurich	3
Brno	2
Chengdu	2
Chongqing	2
Coimbatore	2
Gavirate	2
Graz	2
Legnano	2
Magnago	2
Montreal	2
Monza	2
Muggiò	2
Prague	2
Prescot	2
Quzhou	2
Redmond	2
Rottenburg	2
Rudolfstetten	2
Sesto San Giovanni	2
Shanghai	2
Totale	7.852

Salva come PNG Salva come JPEG

Nome	#
Surface protein components from entomopathogenic nematodes and their symbiotic bacteria: effects on immune responses of the greater wax moth, Galleria mellonella (Lepidoptera: Pyralidae)	169
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4(+) T lymphocytes for immunotherapy	161
Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human	159
The MHC class II transactivator: prey and hunter in infectious diseases	158
New strategies of mammary cancer vaccination	150
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	148
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	145
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	136
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	134
Inflammatory cues acting on the adult intestinal stem cells and the early onset of cancer (Review)	133
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions.	132
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells.	131
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	130
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	129
In Vivo Effects of A Pro-PO System Inhibitor on the Phagocytosis of Xenorhabdus Nematophila in Galleria Mellonella Larvae	127
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	125
The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2	125
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	124
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	115
Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent antitumor preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	114
CIITA-driven MHC-II positive tumor cells: preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy	112
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	110
Therapy-induced antitumor vaccination by targeting tumor necrosis factor  to tumor vessels in combination with melphalan	110
MHC immunoevasins: protecting the pathogen reservoir in infection	109
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	108
Evidence for a specific post-transcriptional mechanism controlling the expression of HLA-DQ, but not -DR and -DP, molecules	106
Antitumor vaccines and immunotherapeutic strategies based on CIITA-driven MHC class II espression in cancer cells.	106
Physiologic target of the Air-1 trans-activator revealed by stable transfection assay	106
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	105
Inflammation, inflammatory cells and angiogenesis: decisions and indecisions	104
The complex liaison between cachexia and tumor burden	104
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	102
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	101
Induction of CIITA and modification of in vivo HLA-DR promoter occupancy in normal thymic epithelial cells treated with IFN-gamma: similarities and distinctions with respect to HLA-DR-constitutive B cells	101
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	96
Therapy-induced antitumor vaccination by targeting TNFa to tumor vessels in combination with melphalan	96
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	94
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	94
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	93
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	93
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	92
Apoptotic DNA binds to HLA class II molecules inhibiting antigen presentation and partecipatine in the development of anti-inflammatory functional behavior of phagocytic macrophages	92
Experimental therapeutic approaches to adenocarcinoma: the potential of tumor cells engineered to express MHC class-II molecules combined with naked DNA interleukin-12 gene transfer	92
CIITA-driven MHC-II+ tumor cells: preventive vaccines and superior generators of anti-tumor CD4+ T lymphocytes for immunotherapy.	92
CIITA reduced transcription as the cause of HLA class II downregulation in human macrophages during bacterial phagocytosis	90
Regulation of HLA antigen expression in HIV infected cells	90
The utility of introducing a measurement of tumor burden for a better assessment of cancer cachexia.	90
Irradiated CIITA-positive mammary adenocarcinoma cells act as potent anti-tumor preventive vaccine by inducine tumor-specific CD4+ T cell priming and CD8+ T cell effector functions	89
Tumor rejection and anti-tumor memory to cancer cells of different histotype genetically modified to express CIITA-driven autologous MHC class II genes. A new strategy of anti-tumor vaccination and tumor immunotherapy.	89
Espressione delle molecole HLA di classe II in cellule di epatocarcinoma classe II negative dopo trasfezione del transattivatore CIITA. Acquisizione della capacità di processare e presentare l'antigene	88
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	87
CIITA-driven MHC class II expressing tumor cells of distinct hystotype act as a potent antitumor vaccine and as a superior generators of tumor-specific CD4+ T lymphocytes for immunotherapy.	87
Analysis of microchimerism in thyroid autoimmune diseases	87
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	87
Higly stable oligomerization forms of HIV-1 Tat detected by Monoclonal antibodies and requirement of monomeric forms for the transactivating function of the HIV-1 LTR	86
Therapy-induced antitumor vaccination by targeting tumor necrosis factor alpha to tumor vessels in combination with melphalan	86
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down-modulation in normal human macrophages during bacterial phagocytosis	86
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	85
Regolazione dell'espressione dei geni del Complesso Maggiore di Istocompatibilità HLA e di CD4 in cellule infettate da HIV: effetto di TAT	85
La presentazione antigenica su molecole di II classe HLA è profondamente alterata in seguito a fagocitosi batterica	84
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	84
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	84
The complex liaison between vulnerability to cachexia and tumor burden.	84
The AIR-1 locus encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 replication by blocking the function of HIV-1 Tat	83
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	83
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	83
Regulation of HLA antigen expression in phagocytes with mycobacteria	82
Imaging guided percutaneous microwave ablation of tumors.	80
The HLA class II transcriptional activator (CIITA) blocks the function of HIV-1 Tat and inhibits viral replication	80
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	80
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	80
Methylation of CIITA promoter IV causes loss of HLA-II inducibility by gamma-IFN in promyelocytic cells	79
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	78
Reduced expression of the AIR-1 gene product CIITA as the cause of HLA class II down modulation in normal human macrophages during bacterial phagocytosis.	78
Induction of tumor regression by gene transfer of the MHC class II transactivator CIITA	77
The MHC class II transactivator is a strong physiologic antagonist of HIV-1 replication	77
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator (CIITA)	77
Irradiated CIITA-positive mammary adenocarcinoma cells act as effective tumor cell vaccine inducing both tumor-specific CD4+ and CD8+ T immune responses and tumor rejection upon challenge.	76
HLA-DQ expression is differently regulated from -DR and -DP	76
The molecular and cellular basis of tumor rejection after vaccination with mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	76
Regulation of HLA antigen expression in phagocytes treated with mycobacteria	76
The replication of HTLV-2 and the expression of HLA class II transcriptional activator (CIITA) are inversely correlated	74
HLA class II-dependent antigen presentation is deeply impaired in macrophage reservoir of infection	73
Tumor vaccination by CIITA-mediated MHC-II-expressing neoplastic cells	73
Constitutive and inducible expression of HLA class II genes in normal cells is under the control of the AIR-1-encoded CIITA trans-activator	73
Control of tumor growth in vivo by gene therapy with the MHC class II transactivator CIITA	72
Inibizione della replicazione virale di HIV-1 e HTLV-2 da parte di CIITA il regolatore trascrizionale dell'espressione dell'HLA-II	72
The immunological basis of tumor rejection and anti-tumor memory to neoplasias of different histotype genetically modified to express CIITA-driven autologous MHC class II genes.	71
Strong adaptive antitumor immune response elicited by targeting tumor necrosis factor a to tumor vessels in combination with melphalan.	71
Temporal and quantitative relations between CIITA and HLA class II expression	71
The MHC class II transactivator (CIITA) mRNA stability is critical for the HLA class II gene expression in differentiating myelomonocytic cells.	70
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	70
La fagocitosi di Mycobacterium Tuberculosis ha effetti opposti sull'espressione di superficie delle molecole HLA di classe I e di classe II	70
Expression of AIR-1/CIITA transactivator in B cell x plasmacytoma somatic cell hybrids restores HLA-DR and -DP expression, but not -DQ	70
The AIR-1 locus-encoded HLA class II transcriptional activator (CIITA) inhibits HIV-1 productive infection by blocking the function of HIV-1 Tat	69
Innate and adaptive immune function of the MHC class II transactivator, CIITA, against human tumor retroviruses HTLV-2 and HTLV-1	69
Reverse correlation between HTLV-II replication and expression of CIITA, the major regulator of HLA class II transcription	68
Induction of tumor rejection by gene transfer of the MHC class II transactivator CIITA	68
Neutrophil and Natural Killer Cell Interactions in Cancers: Dangerous Liaisons Instructing Immunosuppression and Angiogenesis	68
The immunological basis of therapy-induced antitumor vaccination by targeting Tumor Necrosis Factor a to tumor vessels in combination with melphalan	67
Totale	9.571

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	41.166
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	41.166

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2019/2020	1.187	0	0	0	0	69	176	257	240	97	184	17	147
2020/2021	1.447	14	152	8	150	24	161	44	143	264	59	138	290
2021/2022	1.101	141	133	106	111	22	19	41	95	53	128	91	161
2022/2023	1.408	151	66	123	167	97	319	0	188	173	37	51	36
2023/2024	2.827	452	438	505	488	499	220	24	26	107	22	2	44
2024/2025	484	15	49	324	36	60	0	0	0	0	0	0	0
Totale													11.004